A Practical Guide to Small-Molecule Chemical Probes: Concept Clarification, Causal Validation, and Experimental Selection (with Product Navigation and Tables A–D)

Introduction

(1) In life science experiments, we often want to answer a more causal question: Is a given protein actually responsible for the phenotype you observe?

• This is exactly where small-molecule chemical probes come in. A chemical probe is not meant to “visualize” a protein; instead, it is used to directly perturb a protein’s function in cells, thereby connecting target perturbation to phenotypic change more reliably.

 

(2) But in practice, another situation is very common:

• For the same class of small molecules, some people call them “probes,” while others call them “tool compounds.” After completing the experiment, you may indeed see the phenotype change—yet it could be caused by non-specific activity, cytotoxicity, assay/readout interference, or off-target effects. The result is: the data look strong, but the conclusion becomes harder to interpret, and the causal chain becomes weaker rather than stronger.

 

(3) Therefore, this article is organized around one central objective:

How do you select and use small molecules so that your conclusions are closer to “target causality,” rather than a “mixture of compound-driven effects”? The article is developed in 5 steps:

• Concepts and criteria: What is the difference between a tool compound and a chemical probe? When should you not call a molecule a “probe”?
• Experimental advantages: How do chemical probes provide temporal control and dose control, and strengthen causal inference?
• Where probes come from: What can HTS, phenotypic screening, fragment-based approaches, and chem
• 
  
• oproteomics each solve—and where are the most common pitfalls?
• A usable public resource: How to leverage publicly available intracellular interaction / ligandability resources to find “starting points” faster and reduce blind trial-and-error.
• A ready-to-use checklist: The “Good Probe Six-Pack + Three Key Reminders”—a final pre-experiment check.
• Note: In this article, chemical probe specifically refers to probes used to modulate target protein function to support causal attribution. We do not discuss probes in the broader sense of imaging/detection probes.

 

Step 1 | Concepts and Criteria: Tool Compound ≠ Chemical Probe

 

Type	Definition (What it is)	Purpose (Why you use it)	Strength of conclusion it can support
Tool compound	A small molecule used to perturb a biological process/pathway to explore mechanisms or validate a direction	Quickly assess whether a mechanism/pathway might be relevant and whether further validation is worth investing in	Better suited for hypothesis generation / directional judgment; not ideal for direct target-level causal attribution
Chemical probe	A small molecule with a relatively complete evidence chain that can attribute a phenotype to a specific target protein	Establish a causal “target → phenotype” relationship for mechanism studies and target validation	Can support target attribution / causal inference, but still must be stated within its applicability boundaries

 

Note: 

The quality expectations for “chemical probes” here follow common expert-reviewed resources (e.g., the Chemical Probes Portal and public recommendations from SGC). These are closer to experience-based baselines / selection guidelines meant to reduce misinterpretation, and are not hard universal thresholds applicable to all targets. Common focal points include: sufficient potency, explainable selectivity, cellular on-target evidence, and orthogonal probes / matched negative controls (see Step 1.2 and Step 5).

 

1.2 The Difference Is Not “Can You Use It,” but “Is the Evidence Chain Sufficient for Attribution?”

 

Key dimension	Tool compound	Chemical probe
Potency (effectiveness on the intended target)	May have “activity on a target,” but the data may come from limited experiments, be non-comparable across systems, or only show “phenotypic impact” rather than strong target engagement	Requires clear, reproducible quantitative values (e.g., IC₅₀/Kd) with assay conditions, demonstrating it is genuinely strong on-target rather than “working by chance.” This determines whether you can run clean experiments at lower concentrations.
Selectivity	Often lacks systematic information: may hit multiple proteins within the same family or have known frequent off-targets. Acceptable in exploratory stages, but uncertainty must be acknowledged.	Needs data showing minimal impact on “the most easily confounded proteins” (especially same-family members, common off-targets, key safety targets). Selectivity determines whether a phenotype can be primarily attributed to a single target.
Cellular on-target evidence (does it truly hit the target in cells?)	May only show “compound → phenotype.” But the phenotype can arise from toxicity, stress responses, membrane effects, or off-target pathways—not necessarily the intended target.	Requires cellular evidence supporting true target engagement: e.g., target engagement (occupancy/binding) data, or mechanism-consistent hallmark readouts, and the ability to rule out “global cell state disruption.” This is the critical step from correlation toward causality.
Control strategy (how false positives are excluded)	Often only vehicle control, or an “unrelated compound” control—hard to exclude scaffold-driven or physicochemical effects.	Usually expects at least one strong control: a matched negative control (structurally similar but inactive/weakened on-target) and/or an orthogonal probe (a different scaffold that hits the same target). Controls separate “target effects” from “compound side effects.”
Dose and interpretation (how much you use, how you write conclusions)	Frequently needs higher concentrations but the risk is not clearly discussed; higher doses are more likely to hit additional targets, widening interpretation space.	Emphasizes interpreting results within a validated on-target concentration window: aim to generate convergent evidence at lower doses and bind conclusions to specific concentration ranges and conditions to reduce misattribution.
Fit-for-purpose positioning (what problem it is suited to solve)	Suited for exploration/screening: deciding whether a pathway might be relevant and worth pursuing; claims should be more cautious.	Suited for target attribution / mechanism research: supports arguments like “this protein causes this phenotype.” Causal claims can be stronger, but boundary conditions still must be stated.

 

1.3 If You See These Signals, Do Not Treat the Molecule as a “Probe” for Causal Claims

 

Signal (what you observe)	Most likely issue (what it implies)	First-line mitigation (what to do next)
Phenotype appears only at clearly high concentrations	Non-specific hits increase, or the main effect may not be from the intended target	Lower dose with a gradient; add target engagement; switch to a stronger/cleaner molecule
No selectivity data, or known broad-spectrum activity	Off-target effects are hard to exclude	Run family-panel screening / key off-target checks; at minimum add same-family comparisons
Phenotype accompanies obvious cytotoxicity/stress	Phenotype may be driven by toxicity or stress pathways	Add toxicity and stress readouts; use lower dose/shorter exposure windows
No negative control and no orthogonal probe	Scaffold/physicochemical effects cannot be excluded	Add a matched negative control or a second-scaffold (orthogonal) probe
Attribution based on a single phenotype readout	Attribution chain is too short	Add mechanism-linked readouts and orthogonal validation

 

Step 2 | Core Value: Time Control + Dose Control + A Causal Inference Pathway

2.1 Three classes of “controllable variables” chemical probes provide in experimental design

 

Capability (what you can control)	What you can do (operationally)	What it helps answer (typical scenarios)	Why it strengthens interpretability (logic)	Reminder
Time control (fast onset / reversibility)	Add compound at a defined timepoint; reduce/remove effect via washout, withdrawal, or antagonists (reversibility depends on mechanism and how “withdrawal” is done)	Acute processes, rapid signaling, dynamic feedback; distinguishing “early events” from “secondary downstream events”	Constrains intervention to a defined window, helping separate direct effects from downstream effects (clearer temporal order)	Not all small molecules are reversible; cellular retention, irreversible inhibition, or long half-life can make “switching off” incomplete—use time gradients to validate
Dose control (continuous gradient)	Run concentration gradients to obtain dose–response curves; compare thresholds, saturation, nonlinear ranges; distinguish partial vs full inhibition	“Graded intensity” questions: thresholds/saturation, sensitive readout screening, defining a usable concentration window; comparing phenotype sensitivity to the same pathway	Continuous dose information constrains interpretation better than binary “on/off”: orderly dose-dependent changes better support intervention-related causality	High doses more easily trigger off-targets and stress; “effective” ≠ “attributable”—interpret within an explainable window
Causal inference pathway (shrinking off-target explanation space)	Use “multiple lines of evidence for the same conclusion”: the same conclusion holds across different perturbation modes, different scaffolds, and key controls	Mechanism validation, target attribution, reliably linking phenotype to the target protein	When multiple independent pieces of evidence converge on the same target, the space of off-target explanations shrinks substantially	This step relies on Step 1 probe standards and control design; without selectivity/cellular engagement, phenotype alone cannot complete attribution

 

Step 3 | Where Probes Come From: HTS / Phenotypic Screening / FBLD / Chemoproteomics

3.1 Four routes: strengths, blind spots, and “what to add next”

 

Route	What it is good at	Common blind spots / risks	Typical “what to add next”
HTS (High-Throughput Screening)	Rapidly finds initial hits from large libraries that affect a readout / bind / inhibit; fast and broad coverage	Hits often include interferers / frequent hitters: colloidal aggregators, reactive compounds, readout interference (fluorescence/luminescence/redox cycling, etc.); high cost to triage artifacts	Anti-interference & de-artifacting: aggregation/readout checks; SAR reproducibility; orthogonal assays; early selectivity and usable concentration-window assessment
Phenotypic screening	Directly optimizes for functional outcomes; can uncover new mechanisms/pathways without target assumptions	Target deconvolution is difficult; phenotypes may come from multi-target/network effects; mechanistic dissection is slow and needs extra work to reach a “explainable, reproducible target conclusion”	Target identification & causal reinforcement: chemoproteomics/thermal proteome profiling, etc.; genetic cross-validation; improved orthogonal probes and control systems
FBLD (Fragment-Based Lead Discovery)	Uses small fragments to explore binding sites: hits are often weak but ligand-efficient and highly “growable/mergeable” for fine optimization	Requires structural/biophysical/medchem iteration; weak hits make validation more demanding (assay choice, protein quality, false-positive control)	Structural/biophysical confirmation; multi-method triangulation; site-guided fragment growth with property control; gradually add cellular evidence and selectivity boundaries
Chemoproteomics (incl. ABPP, etc.)	Identifies which proteins/sites a compound binds or competes with in near-physiological settings; supports target confirmation, off-target profiling, ligandable-site discovery	Complex interpretation; substantial background binding; high demands on competition experiments, controls, and statistical thresholds—otherwise background may be mistaken as specific	Competition and controls: same-site competition, matched negative controls, dose dependence, replication and statistical control; then close the loop with functional assays and mechanism-linked readouts

 

Step 4 | A Public Resource to Find “Starting Molecules” Faster and Reduce Blind Trial-and-Error

4.1 What problem does it solve?

1. Many people get stuck at the very first step when working with probes/tool molecules:

• “For the protein I care about, is there any small molecule that can bind? What kind of scaffold should I start from?”

The traditional path often requires doing HTS or fragment screening yourself—costly, slow, and uncertain.

 

2. The “public resource” here refers to:

• The Ligand Discovery interactive resource built by Offensperger et al. (Science, 2024). It converts large-scale live-cell chemoproteomics “fragment–protein interaction maps” into searchable data and a web tool, and is paired with machine learning models to help you more quickly locate starting points / chemical scaffolds likely worth optimizing.
• Importantly, it is not a ready-to-use “chemical probe library.” Instead, it is a starting-point navigator: it tells you which fragments are more likely to form capture-able interactions with which proteins in live cells, thereby narrowing the search space for subsequent probe optimization and validation.

 

4.2 What does it solve, and how should you use it?

 

Problem you face when “finding a probe starting point”	What to do in the resource	What usable output you get	You still must return to probe standards (Step 1 & Step 5)
You have a target protein/pathway of interest but don’t know what scaffold to start from	Use Interactions (main entry) to search by protein	Fragment interaction information linked to that protein (to shortlist starting scaffolds)	Still need: potency/selectivity/cellular target engagement + negative controls/orthogonal probes
You have a set of proteins (same family/pathway) and want to see which fragments are more likely to hit the set overall	Use Explore protein sets and input the protein set	Coverage of fragment interactions for that set (more like “starting-point opportunity assessment”)	Still need: target-by-target reproducible validation; exclude background and bias
You worry certain fragments are too promiscuous (sticky everywhere) and will create high background	Use Fragment predictor (behavioral bias prediction)	Predict whether a fragment is more likely broad-spectrum or biased toward certain interaction features	Still need: verify interpretability in your own system with controls and a dose window
You want quick prioritization of candidate interactions, rather than blind screening from scratch	Use On-the-fly modeling for rapid predictive modeling	Interpretable predictive results for your fragment/protein set (for ranking)	Treat predictions as “navigation,” not conclusions; final answers require experimental and control-based closure

 

Reminder: Such public interaction maps solve the “starting-point selection” problem by shrinking the chemical space you would otherwise explore blindly. They do not replace chemical probe standards. To support causal attribution, you still need cellular on-target evidence and matched negative controls / orthogonal probes to close the loop.

 

Step 5 | A Ready-to-Use Checklist: The “Good Probe Six-Pack” + Three Key Reminders

5.1 The Good Probe Six-Pack

 

Six-Pack item	What you need to see (minimum information to report)	Why it matters (what conclusion it directly affects)	What to do if missing (most common fix)
1. Potency: strong enough on the intended target	On-target activity/binding data (IC₅₀, Kᵢ, K_d, etc.) + reproducible concentration–effect relationship; ideally with assay system and conditions	If not strong enough, you’ll be forced into high doses, raising off-target risk—controls may not rescue interpretability	Find a stronger compound / better probe for the same target; or return to in vitro assays to confirm whether the target is truly engaged
2. Selectivity: minimal non-target interference	At least selectivity information versus same-family and high-risk targets; broader profiling when available	Determines whether the phenotype can be primarily attributed to the target; otherwise it behaves like a multi-target tool	Add family panel / key off-target checks; downgrade claim strength to “suggestive association,” not target attribution
3. Cellular on-target evidence: true engagement in cells	Target engagement (prefer direct/proximal measures) or reliable surrogate PD markers; state whether the target is accessible in your cells and whether expression/complex state affects accessibility	The Portal FAQ notes: without target engagement, it’s hard to tell whether “inactive/effective” reflects the target or the system, and hard to define a rational dose window	Use more proximal binding/occupancy assays; or use reliable PD markers to establish an “occupancy–phenotype” relationship
4. Matched negative control: close analog but inactive/weakened on-target	Structurally close (ideally changing only key interaction points) + clearly reduced on-target activity; clarify whether it may still have other off-targets	Excludes non-specific phenotypes driven by scaffold/physicochemical properties	If an ideal negative control is unavailable, at least use a second (orthogonal) scaffold probe (see Item 5) to strengthen causality
5. Orthogonal probe: different scaffold, same target, same-direction effect	Two structurally distinct probes for the same target producing consistent results within a reasonable dose window	The Portal FAQ recommends using two different chemotypes per target, ideally with inactive analogs; distinct scaffolds are unlikely to share the same off-target profile, so consistent effects are more credible	With only one probe, conclusions must be more restrained; prioritize finding a second chemotype via Portal/SGC, etc.
6. Exposure–toxicity boundary: “effective” should not mean “damaging cells”	Run viability/toxicity/stress readouts near effective concentrations; follow recommended maximum dose / empirical upper limits	The Portal also cautions: mere growth inhibition/death is usually not specific; the platform often provides recommended cellular dose caps	Use dose gradients to find the “lowest effective, low-toxicity” window; if needed, switch to a cleaner probe or adjust treatment timing

 

5.2 Three Key Reminders and How to Handle Them

 

Three key reminders	Typical appearance (what you’ll observe)	Common causes (why it happens)	Most effective response
1) Structural alerts / interference compounds: mistaking false positives for hits	The same compound “works” in many unrelated systems; effect disappears when switching assay formats; strong effects without a reasonable dose relationship	PAINS / readout interference, colloidal aggregation, non-specific reactivity, redox cycling, etc.	Run anti-interference checks (aggregation/readout/reactivity); consult Chemical Probes Portal expert reviews and Unsuitables to avoid using compounds unsuitable as probes
2) Cytotoxicity disguised as pathway effects	“Stronger looks better,” but viability drops and stress increases; or effects only appear at high doses	Broad off-targets and cellular collapse at high dose; phenotype becomes non-attributable	Run viability/toxicity/stress readouts near effective doses; bind conclusions to the low-tox window; if needed, switch probes or shorten exposure
3) No controls: making causal claims from a single molecule	Only “one probe + vehicle control,” yet concluding “this target causes this phenotype”	Any single compound can have unknown off-targets; evidence is inherently incomplete. Portal FAQ explains why “orthogonal probe + negative control” is recommended, and also notes negative controls are not foolproof	Prioritize adding a second chemotype probe; add matched negative controls when possible; if neither exists, downgrade claims to “suggestive association / needs further validation,” not “attributed”

 

6. Product Navigation Table | Small-Molecule Chemical Probes / Chemical Proteomics: How to Choose Between Tables A–D

 

Need / scenario (typical question)	Start with which table	Why this table is the best fit	What you can find in this table
Getting started with lysis / sample prep: proteins won’t solubilize, samples are unstable, digestion is inconsistent	Table A	Sample lysis & proteomics sample preparation	If the sample state is not right, downstream click, enrichment, and LC-MS won’t be comparable; background and reproducibility will collapse
After lysis, you need “reduction → alkylation” and worry about disulfide reshuffling or high thiol background	Table A	Sample lysis & proteomics sample preparation	A foundational step in proteomics/chemical proteomics that directly determines labeling consistency and peptide quality
Your probe has an alkyne/azide and you need to “click on” biotin/fluorophore (CuAAC)	Table B	Click chemistry (CuAAC) & copper-removal system	CuAAC success is largely dictated by whether the copper source + reductant + ligand + copper quench/removal are properly matched; this table provides the core kit
Click reaction is incomplete / signal is weak: nothing shows up on gel or LC-MS enrichment	Table B	Click chemistry (CuAAC) & copper-removal system	Common causes cluster around insufficient generation/stabilization of Cu(I), mismatched ligands, or copper being consumed by impurities—checking the catalytic system first is most efficient
High background, protein oxidation, yellowing samples: suspect copper-mediated side reactions	Table B	Click chemistry (CuAAC) & copper-removal system	You generally need a more biocompatible ligand + thorough copper quenching/removal to suppress copper-related background
Installing a handle/linker/tag onto a parent scaffold: making probe derivatives or intermediates	Table C	Probe derivatization & coupling activation	The core of probe construction: activation → coupling → handle/linker introduction
Coupling/acylation in organic phase is slow / low yield and needs catalysis or acid scavenging	Table C	Probe derivatization & coupling activation	Key is whether the coupling reagent + base + catalyst combination is合理/appropriate
Building covalent probes / reactive fragments: focusing on Cys reactivity, wanting a warhead or to cap background	Table D	Enrichment & “probe-enabling” modules	This table groups covalent labeling + background control + quench/competition controls, which best matches covalent-probe/ABPP workflows
Need pull-down enrichment: streptavidin/avidin systems, or want mild elution	Table D	Enrichment & “probe-enabling” modules	Enrichment tags and elution strategy determine whether you can pull down efficiently, wash cleanly, and recover well
Want photoaffinity probes: “freeze” transient binding for identification	Table D	Enrichment & “probe-enabling” modules	Photo-crosslinking is a probe structural module and is often combined with click/enrichment to form a complete evidence chain
Preparing stock solutions / treating cells / making LC-MS mobile phases: worried about solubility and MS background	Table D	Enrichment & “probe-enabling” modules	Solvents and acidic additives define the usable concentration window and strongly affect MS background/ionization

 

Summary:

1. Get sample handling running smoothly → see Table A

2. Probe has a handle and needs CuAAC → see Table B

3. Need to synthesize/derivatize the probe molecule itself → see Table C

4. Need enrichment / covalent labeling / photo-crosslinking / solvents & LC-MS additives → see Table D

 

Table A | Sample Lysis & Proteomics Sample Preparation (Denaturation / Detergents / Reduction–Alkylation / Buffers / Water)

 

Category	CAS No.	Aladdin Cat. No.	Name	Spec / Purity	Use & selection notes (small-molecule probes)
Ultrapure water / system water	7732-18-5	W123529	Cell-biology-grade water	For cell biology; endotoxin-free, pyrogen-free; ultrafiltered and autoclaved	Use high-purity water for cell/proteomics workflows to reduce background fluctuations from endotoxin and impurities; for preparing click/buffer/wash systems.
Proteomics / sample lysis | Denaturant	57-13-6	U432962	Urea	Beads	Common protein denaturant/solubilizer for lysis and unfolding to expose binding sites and improve digestion efficiency; in proteomics prep it is typically diluted to low concentration to avoid inhibiting enzymes and to reduce MS background.
Proteomics / sample lysis | Strong denaturant	50-01-1	G108675	Guanidine hydrochloride	For protein analysis, ≥99.5%	Strong denaturant/solubilizer: useful for difficult proteins and complexes; for probe enrichment/proteomics prep it is typically diluted/exchanged to remain compatible with digestion and MS.
Proteomics / sample lysis | Detergent	151-21-3	S432158	Sodium dodecyl sulfate (SDS)	For electrophoresis; anionic	Strong anionic surfactant commonly used to lyse and solubilize membrane proteins/complexes; however it markedly interferes with tryptic digestion and LC-MS, so it usually needs removal before MS (lower background, better reproducibility).
Protein sample handling | Reductant (break disulfides)	3483-12-3	D104861	DL-Dithiothreitol (DTT)	For electrophoresis, ≥99%	High-frequency reagent for disulfide reduction; used in proteomics prep (reduction → alkylation) and before thiol reactions to improve labeling and digestion consistency.
Protein sample handling | Reductant (stable)	51805-45-9	T755610	Tris(2-carboxyethyl)phosphine hydrochloride (TCEP·HCl)	UltraBio™; suitable for electrophoresis; SDS-PAGE tested	Stable aqueous reductant for disulfide reduction, with fewer thiol-related side reactions; commonly used in proteomics reduction steps and as pretreatment before thiol reactions.
Protein sample handling | Cys alkylation/capping	144-48-9	I131590	Iodoacetamide (IAA)	Moligand™, ultrapure, ≥99% (NMR)	Classic proteomics alkylation reagent: caps Cys after reduction to prevent re-oxidation/disulfide reshuffling; also used to evaluate thiol-related background and labeling consistency.
Proteomics | Volatile buffer salt	1066-33-7	A110536	Ammonium bicarbonate	Reagent grade	Volatile buffer salt commonly used for proteomics digestion (LC-MS compatible); used for trypsin digestion and building buffering systems prior to desalting.
Thiol chemistry | Reduction/maintenance	60-24-2	M301574	β-Mercaptoethanol	For cell culture; suitable for electrophoresis; molecular-biology grade, ≥99%	Reducing additive used to maintain thiols in the reduced state and reduce disulfide reshuffling; can also serve as a quencher after covalent probes/thiol reactions to lower background from residual electrophiles.

 

Table B | Click Chemistry (CuAAC) & Copper-Removal System (Copper source / reductant / ligand / quench)

 

Category	CAS No.	Aladdin Cat. No.	Name	Spec / Purity	Use & selection notes (small-molecule probes)
Click chemistry | Copper source (Cu(II) precursor)	7758-99-8	C112412	Copper(II) sulfate pentahydrate	For plant cell culture, ≥98%	Common Cu(II) source for CuAAC; paired with sodium ascorbate to generate Cu(I) in situ to catalyze azide–alkyne click coupling—useful for “clicking on” tags to probe handles.
Click chemistry | Direct Cu(I) source	7787-70-4	C104701	Copper(I) bromide	PrimorTrace™, ≥99.99% metals basis	Frequently used Cu(I) salt for CuAAC; with ligands it improves Cu(I) stability and reaction efficiency—useful for condition screening.
Click chemistry | Direct Cu(I) source	7681-65-4	C433811	Copper(I) iodide	Anhydrous, ≥99.995% metals basis	Direct Cu(I) source for CuAAC; often combined with ligands (TBTA/THPTA) to improve stability and click efficiency—useful for screening/optimization.
Click chemistry | Reductant (generate Cu(I))	134-03-2	S105026	Sodium ascorbate	For cell culture, ≥99%	Standard CuAAC reductant: reduces Cu(II) to Cu(I) to form the active catalyst; used for assembling and optimizing click reaction systems.
Click chemistry | CuAAC ligand (biocompatible)	760952-88-3	T405015	Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA)	≥97%	Common aqueous CuAAC ligand: improves click efficiency and reduces copper-mediated oxidative damage; widely used in lysate/protein sample click and chemical proteomics workflows.
Click chemistry | CuAAC ligand (classic)	510758-28-8	T162437	Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA)	≥95%	Classic CuAAC ligand: stabilizes Cu(I) and improves selectivity; often used for condition screening (in aqueous systems it typically requires co-solvents or solubility optimization).
Metal chelation / termination | Metal removal / background control	6381-92-6	E118596	Disodium EDTA dihydrate	For plant cell culture, ≥99%	Chelates metal ions to suppress metal-catalyzed side reactions and protect samples; after CuAAC it can be used to terminate/de-copper and reduce copper-related oxidation and background.
Click termination / de-copper | Selective Cu(I) chelator	52698-84-7	D303893	Bathocuproine disulfonate disodium salt	≥97%	BCS: highly selective for Cu(I); used for rapid post-click quenching and copper removal to reduce copper-related oxidation and nonspecific background.

 

Table C | Probe Derivatization & Coupling Activation (EDC/NHS/DCC + base/catalyst + handle / alternative linkage)

 

Category	CAS No.	Aladdin Cat. No.	Name	Spec / Purity	Use & selection notes (small-molecule probes)
Coupling activation | Water-soluble carbodiimide	25952-53-8	A638729	Aladdin™ EDC	Analytical standard	Core reagent for carboxyl–amine coupling; frequently used to attach handles/linkers/tags to parent molecules or carriers (more aqueous-leaning systems), a high-frequency tool for probe derivatization.
Coupling activation | NHS additive (active-ester formation)	6066-82-6	H109330	N-Hydroxysuccinimide (NHS)	≥98%	Used with EDC/DCC to form NHS active esters and boost carboxyl–amine coupling efficiency; used to build probe intermediates that can further accept handles/tags.
Coupling activation | Organic-phase carbodiimide	538-75-0	D432856	N,N′-Dicyclohexylcarbodiimide solution (DCC)	1.0 M in methylene chloride	Common organic-phase coupling reagent for amide/ester formation and linker construction; suitable for the organic synthesis stage of probe derivatization (often higher efficiency with NHS/DMAP/base).
Coupling activation | Base (for coupling)	7087-68-5	N433364	N-Ethyl diisopropylamine solution (DIPEA)	For peptide synthesis, ~2 M in 1-methyl-2-pyrrolidinone	Common organic base for scavenging acid and driving coupling in EDC/NHS or DCC systems; useful in linker/tag derivatization and peptide/probe synthesis steps.
Coupling activation | Acylation catalyst	1122-58-3	D109207	4-Dimethylaminopyridine (DMAP)	≥99%	Common catalyst for acylation/esterification; improves DCC/active-ester coupling efficiency; widely used in linker/tag/probe derivative synthesis.
Probe handle | Alkyne building block	2450-71-7	p103552	Propargylamine	≥98%	Most commonly used alkyne handle building block; introduces an alkyne into the parent scaffold (enabling downstream CuAAC/SPAAC attachment of biotin/fluorophores).
Bioorthogonal | Staudinger phosphine reagent	603-35-0	T104475	Triphenylphosphine	≥99% (GC)	Classic phosphine reagent: used for azide-related Staudinger reduction/ligation logic (an alternative/orthogonal route or control chemistry beyond click), and also widely used in organic reductions.

 

Table D | Enrichment & “Probe-Enabling” Modules (Biotin system + covalent/thiol chemistry + photo-crosslinking + common solvents / LC-MS additives)

 

Category	CAS No.	Aladdin Cat. No.	Name	Spec / Purity	Use & selection notes (small-molecule probes)
Enrichment tag | Biotin core	58-85-5	B476742	Biotin	PharmPure™, USP	Core affinity enrichment tag for streptavidin/avidin pull-down and enrichment; also used for competitive elution and system validation.
Enrichment tag | Amine-reactive biotinylation	35013-72-0	A638743	Aladdin™ NHS-Biotin	≥99%	Biotin-NHS ester: rapidly couples to amines (Lys/N-terminus) for biotinylation; used to build biotinylated probes/linkers or to prepare biotinylated control samples to validate pull-down workflows.
Enrichment tag | Reversible enrichment / mild elution	533-48-2	R303913	D-Desthiobiotin	≥95%	Desthiobiotin binds streptavidin but is more readily displaced by biotin, enabling easier/milder competitive elution; suitable when gentle recovery and reduced irreversible adsorption are needed.
Thiol site coupling | Maleimide group	541-59-3	M100788	Maleimide	≥98%	Preferentially reacts with Cys-SH: used to construct “maleimide-tag/linker/probe” for thiol-site coupling; common in site-specific labeling and conjugation strategies.
Thiol chemistry | Capping / background control	128-53-0	E100553	N-Ethylmaleimide (NEM)	Moligand™, ultrapure, ≥99%	Rapidly caps free thiols (Cys-SH); often used post-lysis to cap/control background, reducing interference from nonspecific thiol reactions and disulfide exchange in probe readouts.
Covalent chemistry | Cys-electrophile warhead	79-07-2	C106072	Chloroacetamide	≥99%	Strong electrophile for Cys-SH: used in covalent probe/reactive fragment design and as a control; dose and reaction time should be controlled to reduce broad nonspecific labeling.
Covalent chemistry | Michael acceptor core / control	79-06-1	A108470	Acrylamide	Moligand™, for electrophoresis, ≥99%	Structural core/control for Michael-acceptor warheads (also used in electrophoresis); practical covalent probes are typically “scaffold–acrylamide” and require tuning reactivity/selectivity to avoid broad nonspecific labeling.
Nucleophile / quencher | Thiol (control/competition)	52-90-4	L755721	L-Cysteine	UltraBio™, ≥98.5% (RT)	Thiol nucleophile: used as a quencher/competitor control for covalent probes/electrophiles to distinguish specific labeling from nonspecific reactivity background.
Nucleophile / quencher | Antioxidant / thiol precursor	616-91-1	A105421	N-Acetyl-L-cysteine (NAC)	PharmPure™, USP, Ph.Eur, ≥98.5%	Widely used antioxidant and thiol-related control reagent: helps reduce oxidative-stress background and can serve as a quencher/control for reactive electrophiles (often used in covalent probe workflows and boundary-condition checks in sample handling).
Nucleophile / quencher | Intracellular reducing-system control	70-18-8	G105427	Glutathione (reduced, GSH)	Moligand™, for cell culture, ≥98%	Major intracellular reductant: used to assess stability/“quenching risk” of covalent probes/electrophiles under reducing conditions; also used in competition/quenching experiments to lower nonspecific reactivity background.
Photoaffinity module | Benzophenone core	119-61-9	B431545	Benzophenone	For synthesis	Classic photoaffinity module core; used to build photo-crosslinking probes (UV-triggered covalent capture) to convert transient interactions into identifiable signals.
Photoaffinity module | Benzophenone derivative	134-85-0	C100737	4-Chlorobenzophenone	≥99%	Benzophenone photo-crosslinking derivative; used to synthesize photo-crosslinkable probe scaffolds (UV-triggered covalent capture), facilitating downstream enrichment/identification.
Photoaffinity module | Benzophenone derivative	611-94-9	M136425	4-Methoxybenzophenone	≥98% (GC)	Benzophenone photo-crosslinking derivative; used to build photoaffinity probes and enable UV covalent capture, supporting interaction identification and target attribution.
Solvent | Stock solution / cell treatment	67-68-5	D103280	Dimethyl sulfoxide (DMSO)	Pharmaceutical grade, PharmPure™	Most common solvent for probe/small-molecule stocks; convenient for dose-response and cell treatment (typically control the final % to reduce cellular stress/false positives).
Solvent | Synthesis/coupling (polar aprotic)	68-12-2	D119450	N,N-Dimethylformamide (DMF)	Anhydrous, ≥99.8%	Common coupling/derivatization solvent for installing linkers/handles in organic synthesis; also used to prepare some poorly soluble probe intermediates.
Solvent | Proteomics precipitation/wash	67-56-1	M433281	Methanol	Preparative chromatography grade	Common for protein precipitation/washing, desalting/defatting, and LC-MS systems; helps lower impurity background and improve run stability.
Solvent | LC-MS routine solvent	75-05-8	A433541	Acetonitrile (ACN)	For DNA synthesis, H₂O ≤10 ppm	High-frequency solvent in LC-MS/proteomics: for mobile phases, elution, and sample handling; low water/low impurities helps reduce background and improve reproducibility.
LC-MS additive | Acid (sample/mobile phase)	64-18-6	F433212	Formic acid (FA)	Pharmaceutical grade, PharmPure™, ≥98%	Most common acidifier in proteomics/LC-MS (e.g., 0.1%); improves peak shape and is ESI-compatible, suitable for LC-MS runs and desalting workflows.
LC-MS additive | Acid (sample/mobile phase)	76-05-1	T433653	Trifluoroacetic acid solution (TFA)	For protein sequencing, 25% solution in water	Often used for peptide dissolution, RP conditions, and some separations; for MS note that TFA can suppress ESI ionization—typically keep it low in LC-MS methods or switch to FA-based systems.

 

Note: The above are representative Aladdin products. For more specifications, please refer to the full product list at the end of the article or search the Aladdin website by product name/CAS number.

 

 

Aladdin: https://www.aladdinsci.com/